962 related articles for article (PubMed ID: 28833869)
61. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
[TBL] [Abstract][Full Text] [Related]
62. Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy.
Bhadhuri A; Kind P; Salari P; Jungo KT; Boland B; Byrne S; Hossmann S; Dalleur O; Knol W; Moutzouri E; O'Mahony D; Murphy KD; Wisselink L; Rodondi N; Schwenkglenks M
Health Qual Life Outcomes; 2020 Sep; 18(1):317. PubMed ID: 32993637
[TBL] [Abstract][Full Text] [Related]
63. The EQ-5D-5L Value Set for England: Response to the "Quality Assurance".
van Hout B; Mulhern B; Feng Y; Shah K; Devlin N
Value Health; 2020 May; 23(5):649-655. PubMed ID: 32389231
[TBL] [Abstract][Full Text] [Related]
64. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
65. EQ-5D-5L norms for the urban Chinese population in China.
Yang Z; Busschbach J; Liu G; Luo N
Health Qual Life Outcomes; 2018 Nov; 16(1):210. PubMed ID: 30409137
[TBL] [Abstract][Full Text] [Related]
66. Elicitation of Norwegian EQ-5D-5L values for hypothetical and experience-based health states based on the EuroQol Valuation Technology (EQ-VT) protocol.
Hansen TM; Helland Y; Augestad LA; Rand K; Stavem K; Garratt A
BMJ Open; 2020 Jun; 10(6):e034683. PubMed ID: 32532768
[TBL] [Abstract][Full Text] [Related]
67. The Indonesian EQ-5D-5L Value Set.
Purba FD; Hunfeld JAM; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Ramos-Goñi JM; Passchier J; Busschbach JJV
Pharmacoeconomics; 2017 Nov; 35(11):1153-1165. PubMed ID: 28695543
[TBL] [Abstract][Full Text] [Related]
68. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients.
Pan CW; Sun HP; Wang X; Ma Q; Xu Y; Luo N; Wang P
Qual Life Res; 2015 Jul; 24(7):1767-74. PubMed ID: 25540029
[TBL] [Abstract][Full Text] [Related]
69. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L Value Sets.
Kularatna S; Chen G; Byrnes J; Scuffham PA
Value Health Reg Issues; 2017 May; 12():20-23. PubMed ID: 28648311
[TBL] [Abstract][Full Text] [Related]
70. EQ-5D self-reported health in Barbados and Jamaica with EQ-5D-5L population norms for the English-speaking Caribbean.
Bailey H; Janssen MF; La Foucade A; Boodraj G; Wharton M; Castillo P
Health Qual Life Outcomes; 2021 Mar; 19(1):97. PubMed ID: 33741000
[TBL] [Abstract][Full Text] [Related]
71. Cross-Attribute Level Effects Models for Modeling Modified 5-Level Version of EQ-5D Health State Values: Is Less Still More?
Yang Z; Rand K; Busschbach J; Luo N
Value Health; 2023 Jun; 26(6):865-872. PubMed ID: 36566885
[TBL] [Abstract][Full Text] [Related]
72. Health problems are more common, but less severe when measured using newer EQ-5D versions.
Craig BM; Pickard AS; Lubetkin EI
J Clin Epidemiol; 2014 Jan; 67(1):93-9. PubMed ID: 24075597
[TBL] [Abstract][Full Text] [Related]
73. Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease.
Gandhi M; Tan RS; Lim SL; Rand K; Lam CSP; Luo N; Cheung YB
Value Health; 2022 Mar; 25(3):451-460. PubMed ID: 35227458
[TBL] [Abstract][Full Text] [Related]
74. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
[TBL] [Abstract][Full Text] [Related]
75. A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states.
Norman R; Cronin P; Viney R
Appl Health Econ Health Policy; 2013 Jun; 11(3):287-98. PubMed ID: 23649892
[TBL] [Abstract][Full Text] [Related]
76. Valuing health-related quality of life among the Indian population: a protocol for the Development of an EQ-5D Value set for India using an Extended design (DEVINE) Study.
Jyani G; Prinja S; Kar SS; Trivedi M; Patro B; Purba F; Pala S; Raman S; Sharma A; Jain S; Kaur M
BMJ Open; 2020 Nov; 10(11):e039517. PubMed ID: 33444194
[TBL] [Abstract][Full Text] [Related]
77. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
[TBL] [Abstract][Full Text] [Related]
78. New Zealand Population Norms for the EQ-5D-5L Constructed From the Personal Value Sets of Participants in a National Survey.
Sullivan T; Turner RM; Derrett S; Hansen P
Value Health; 2021 Sep; 24(9):1308-1318. PubMed ID: 34452711
[TBL] [Abstract][Full Text] [Related]
79. Reporting and valuing one's own health: a think aloud study using EQ-5D-5L, EQ VAS and a time trade-off question among patients with a chronic condition.
Ernstsson O; Burström K; Heintz E; Mølsted Alvesson H
Health Qual Life Outcomes; 2020 Dec; 18(1):388. PubMed ID: 33334348
[TBL] [Abstract][Full Text] [Related]
80. The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia.
Norman R; Mulhern B; Lancsar E; Lorgelly P; Ratcliffe J; Street D; Viney R
Pharmacoeconomics; 2023 Apr; 41(4):427-438. PubMed ID: 36720793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
